上海，2026年10月20日——药明康德（603259）今日宣布，公司荣获全球增长咨询机构弗若斯特沙利文(Frost&Sullivan)颁发的“2026全球CRDMO年度公司奖”。这是药明康德（603259）连续第十年获得该机构的认可。
弗若斯特沙利文高度肯定公司一体化CRDMO业务模式的价值。该模式覆盖从早期发现到商业化生产的新药研发全流程，为客户提供贯穿药物研发全生命周期（883436）的服务。同时，药明康德（603259）的全球产能布局、稳健的运营表现，以及应对日益复杂的新分子类型的能力，充分体现了公司的差异化优势。
“药明康德（603259）凭借持续满足客户不断变化的创新需求在行业中脱颖而出，”弗若斯特沙利文医疗健康与生命科学业务副总裁Unmesh Lal表示，“作为全球生物医药创新领域值得信赖的合作伙伴，药明康德（603259）始终致力于帮助客户取得成功。”
“我们很荣幸再次获得弗若斯特沙利文的认可，这是对药明康德（603259）持续为客户创造价值的肯定。”药明康德（603259）董事长兼首席执行官李革博士表示，“作为行业坚定的赋能者，我们将继续聚焦CRDMO核心战略，助力全球客户加快创新疗法的研发进程，造福全球病患。”
弗若斯特沙利文“年度公司奖”是该机构的最高荣誉，旨在表彰那些在前瞻性创新、市场领先地位以及客户服务方面表现卓越的企业。
关于药明康德
药明康德（603259）(股票代码：603259.SH/2359.HK)是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的“CRDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球30多个国家的合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com WuXi AppTec Receives Frost&Sullivan’s Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year SHANGHAI,October19,2026–WuXi AppTec,a leading global pharmaceutical CRDMO(Contract Research,Development,and Manufacturing Organization),has received Frost&Sullivan’s2026Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year.
Frost&Sullivan highlighted WuXi AppTec’s integrated CRDMO model,which enables the company to support customers across the full drug development lifecycle,from early discovery through commercial manufacturing.The firm noted WuXi AppTec’s global capacity,operational consistency,and ability to adapt to increasingly complex modalities as key differentiators.
“WuXi AppTec distinguishes itself through its strong focus on evolving customer needs,”said Unmesh Lal,Vice President of Healthcare and Life Sciences at Frost&Sullivan.“Its commitment to customer success reinforces its position as a trusted partner to biopharmaceutical innovators worldwide.”
“We are honored that Frost&Sullivan has once again recognized what our teams deliver every day for customers,”said Dr.Ge Li,Chairman and CEO of WuXi AppTec.“As a dedicated enabler of the pharmaceutical industry,we remain committed to our CRDMO Strategy（MSTR） and to helping customers around the world bring life-changing therapies to patients faster.”
Frost&Sullivan’s Company of the Year Recognition is its top honor,recognizing companies that exemplify visionary innovation,market-leading performance,and unmatched customer care.
About WuXi AppTec WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries,providing R&D and manufacturing services that help advance healthcare innovation.With operations across Asia,Europe,and North America,we offer integrated,end-to-end services through our unique CRDMO(Contract Research,Development,and Manufacturing Organization)platform.We are privileged to work alongside partners across30+countries,supporting their efforts to bring breakthrough treatments to patients.Guided by our vision that every drug can be made and every disease can be treated,we are committed to advancing breakthroughs for patients—one collaboration at a time.Learn more at www.wuxiapptec.com.
